Exclusive Online Content
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
Eagle Pharmaceuticals, Inc. recently announced it has reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia Pharma Group plc to Eagle by way of a scheme of arrangement under….
Ionis & Biogen Announce Topline Phase 1 Study Results
Ionis Pharmaceuticals, Inc. & Biogen, Inc. recently announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people…
DFE Pharma, Harro Höfliger & Sterling Announce Unique Partnership to Provide Formulation Services for Respiratory Products
Three leading companies in their respective fields – DFE Pharma (excipients solution provider), Harro Höfliger (equipment supplier), and Sterling (API manufacturer) recently announced a unique partnership….
Gerresheimer Opens a New Plant to Produce Pharmaceutical Container Solutions
Gerresheimer ceremoniously took over a new building in Berlin, Ohio. In the future, the square plastic containers of the Duma Twist-Off Q brand with a 40-ml filling volume….
GeoVax Announces Issuance of Cancer Vaccine Patent
GeoVax Labs, Inc. recently announced the U.S. Patent and Trademark Office has issued Patent No. 11278607 to GeoVax, pursuant to the company’s patent application No. 16/068,527 titled….
Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for Investigational Gene-Based Treatment to Address the Underlying Biology of Aging Skin
Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc., recently announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301….
Lonza Partners With Oasmia Pharmaceuticals to Manufacture Ovarian Cancer Therapy
Oasmia Pharmaceutical AB and Lonza recently announced the companies have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of….
Chiesi & Protalix Announce Phase 3 Data From BRIGHT Study in Fabry Disease
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., recently announced final results from the BRIGHT Phase 3 clinical trial evaluating pegunigalsidase alfa….
physIQ & CellCarta Collaborate to Accelerate a More Precise, Personalized Approach to Vaccine Development
physIQ and CellCarta recently announced a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development…..
PAVmed Announces Successful First-in-Human Implantations of its Intraosseous Infusion System
PAVmed Inc. recently announced physicians at the Clinica Porto Azul in Barranquilla, Colombia, successfully implanted the company’s PortIO Intraosseous Infusion System in three….
EXCLUSIVE ONLINE CONTENT
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….
Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership
Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….
Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases & $280-Million Private Placement
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication….
BC Platforms & NTT Group Announce Official Opening Ceremony for Exclusive Collaboration & Launch of Japanese Precision Medicine Platform
BC Platforms (BCP) recently announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven….